Santarus Inc (SNTS1)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Employees:
3611 VALLEY CENTRE DRIVE, STE 400, SAN DIEGO, CA 92130
8583145700

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

N/A

Data derived from most recent annual or quarterly report
Market Cap 2.019 Billion Shares Outstanding63.17 Million Avg 30-day Volume 2.215 Million
P/E Ratio14.0038 Dividend Yield0.0 EPS1.87
Price to Revenue5.3089 Debt to Equity0.0 EBITDA80.796 Million
Price to Book Value7.832 Operating Margin21.9571 Enterprise Value1.625 Billion
Current Ratio3.487 EPS Growth6.5 Quick Ratio2.763
1 Yr BETA 1.82975 52-week High/Low 0.0 / Profit Margin37.9102
Operating Cash Flow Growth153.5034 Altman Z-Score14.8845 Free Cash Flow to Firm 70.121 Million
View SEC Filings from SNTS1 instead.

View recent insider trading info

Funds Holding SNTS1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SNTS1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SALIX PHARMACEUTICALS LTD

SALIX PHARMACEUTICALS, INC.

WILLOW ACQUISITION SUB CORP

  • 10% Owner
100 2014-01-02 0

HALE DAVID F

  • Director
No longer subject to file 2014-01-02 0

HERMAN MICHAEL E

  • Director
No longer subject to file 2014-01-02 0

CREECH TIMOTHY J PRESIDENT

  • Officer
  • Director
0 2014-01-02 0

LOVE TED W

  • Director
No longer subject to file 2014-01-02 0

WIERENGA WENDALL EVP, R&D

  • Officer
No longer subject to file 2014-01-02 0

BURGESS DANIEL D

  • Director
No longer subject to file 2014-01-02 0

CARTER MICHAEL G

  • Director
No longer subject to file 2014-01-02 0

PROEHL GERALD T PRESIDENT & CEO

  • Officer
  • Director
No longer subject to file 2014-01-02 0

CRAWFORD DEBRA P SR. VP, CFO, SEC'Y, TREAS

  • Officer
No longer subject to file 2014-01-02 0

DENBY WILLIAM C SR. VP, COMMERCIAL OPERATIONS

  • Officer
No longer subject to file 2014-01-02 0

HALL WARREN E SR. VP, MFG. & PROD. DEV.

  • Officer
No longer subject to file 2014-01-02 0

DE MEULES JULIE A SR. VP, HUMAN RESOURCES

  • Officer
No longer subject to file 2014-01-02 0

SNYDER KENT

  • Director
No longer subject to file 2014-01-02 0

BERTRAND WILLIAM C JR SECRETARY

  • Officer
  • Director
0 2014-01-02 0

STEP MICHAEL D SVP, CORPORATE DEVELOPMENT

  • Officer
No longer subject to file 2014-01-02 0

BALLARD E DAVID II SVP, MED AFFAIRS & PHARM'VIG

  • Officer
No longer subject to file 2014-01-02 0

FOX CAREY J SR VP, GENERAL COUNSEL

  • Officer
No longer subject to file 2014-01-02 0

BEDOYA-TORO MARIA E SVP, REGULATORY AFFAIRS & QA

  • Officer
No longer subject to file 2014-01-02 0

TOTORITIS MARK SVP, CLINICAL RESEARCH

  • Officer
No longer subject to file 2014-01-02 0

DELLA CHA ALESSANDRO

  • Director
No longer subject to file 2014-01-02 0

COSMO TECHNOLOGIES LTD

CIPRIANO GIUSEPPE

COSMO HOLDING S.P.A.

COSMO PHARMACEUTICALS S.P.A.

AJANI MAURO

MORO LUIGI

  • 10% Owner
  • RELATED ENTITYRELATED ENTITYRELATED ENTITYRELATED ENTITYRELATED ENTITY
No longer subject to file 2013-05-15 0

STROBECK MATTHEW

  • Director
0 2012-05-15 0

CASSIOPEA SA

CIPRIANO GIUSEPPE

MORO LUIGI

AJANI MAURO

COSMO PHARMACEUTICALS SPA

COSMO HOLDING S.P.A.

COSMO TECHNOLOGIES, LTD.

  • 10% Owner
6,000,000 2008-12-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments